Beat the Market with Just 3 Stocks📈

Don't miss these red-hot stocks... [Image](www.elitetrade.club) Good Morning! Hey, guys and gals. It's Chris from Elite Trade Club, here to give you the day's premarket trading news. Today is Wednesday, August 3rd. Let's get ready to trade! Markets 📈 The S&P 500 slid to a 0.7% loss yesterday, while the Nasdaq fell 0.2%. The Dow lost 1.2% on the session, and the small-cap Russell 2k was down 0.1%. Today, futures are on the rise ahead of the opening bell.S S&P 500 contracts are up 0.3%. Sponsored [Beat the Market with Just 3 Stocks]( When most folks think about making money through the markets, they think “buy and hold.” They think “diversification.” And they think about investing in things like index funds. But one man has a different approach… It’s called the “3-Stock Retirement Blueprint.” It’s a way to play 3 stocks — yes, just 3 — and potentially make more money than you would by trading all the rest of them… [Get all the details here — including the names and tickers of the three stocks.]( Premarket Highlights 🔎 - Gasoline prices have fallen for 49 straight days and are approaching $4 per gallon. - Robinhood Crypto fined $30 million by New York's top financial regulator. What to Watch Today 👀 Earnings Earnings season rolls on with reports from big names like Toyota Motor, CVS Health, Moderna, Yum Brands, and more. Today's slate of reports should give investors more insights into the state of the country's economic recovery. International 🌍 Asia China's Shanghai Composite lost 0.7% overnight, while Japan's Nikkei 225 added 0.5%. The Hang Seng added 0.4% in Hong Kong. Europe Germany's DAX and France's CAC 40 are both showing 0.2% gains midway through their session. The Euro Stoxx 600 is up 0.1%. Major Earnings 💰 - CVS Health [CVS] ... AM - Moderna [MRNA] ... AM - Regeneron Pharmaceuticals [REGN] ... AM - Enterprise Products Partners [EPD] ... AM - Exelon [EXC] ... AM - Booking Holdings [BKNG] ... PM - McKesson [MCK] ... PM - MetLife [MET] ... PM - Fortinet [FTNT] ... PM - Nutrien [NTR] ... PM - Realty Income [O] ... PM Economy 🏗 - S&P U.S. services PMI (final) [Jul] ... 9:45a - ISM services index [Jul] ... 10a - Factory orders [Jun] ... 10a - Core capital equipment orders (revision) [Jun] ... 10a Running Hot 🔥 Gainers - Eargo [EAR] >> +118.6% - Helius Medical A [HSDT] >> +221.9% - ChemBio [CEMI] >> +65.8% Decliners - MMTEC Inc [MTC] >> (19.9%) - Hydrofarm [HYFM] >> (23.6%) - Match Group [MTCH] >> (21.3%) PayPal Holdings [PYPL] - Last Close: $84.85 PayPal is getting a boost from its latest earnings report. The payment processing stock released its Q2 results on Tuesday evening, and investors are buzzing. PayPal reported adjusted EPS of $0.93 per diluted share on revenues of $6.81 billion, which topped the Street's expectation of $0.87 EPS on $6.78 billion in sales. However, PayPal's Q3 and full-year guidance came in slightly below analyst expectations. The biggest story to come out of the report was PayPal's disclosure that activist investing firm Elliott Management has taken a $2 billion stake in the company. PYPL is leading the S&P 500 with a 12.6% gain on active volume. Our Take: Elliott Management's push into PayPal could be good news for shareholders. The activist firm has a talent for squeezing profits out of companies and pushing them towards more aggressive growth. I am liking PayPal on a pullback here. SoFi Technologies [SOFI] - Last Close: $6.41 SoFi Technologies is trending after an upbeat earnings report. The digital financial services stock reported Q2 results that beat the Street's expectations for both earnings and revenues. SoFi reported a Q2 loss of $0.12 per share, which narrowly topped analysts' prediction of a $0.13 per share loss. Net revenues of $356.09 million were 50% higher than the year-earlier quarter and beat the Street's target of $346.48 million. SoFi also reported it added 450,000 new members in the quarter, and the company raised its full-year guidance in response to the strong quarter. SOFI is up 11.5% in today's premarket. Our Take: SOFI's growth numbers look good, but it's always tough for company's like this when the market is struggling. I would be cautious before jumping into this one with both feet, as I'm fairly confident they'll see a slowdown in Q3. Applied DNA Sciences [APDN] - Last Close: $2.80 A new clinical update is skyrocketing shares of Applied DNA. The genetic testing firm announced Tuesday that it's validating a newly-developed PCR-based test that can detect the monkeypox virus. If the test is validated, the company will submit a validation package to the NY State Dept. of Health for approval. If approved, Applied DNA's test will become New York's go-to choice monkeypox testing programs. APDN surged to a 311.2% gain in yesterday's session following the announcement, and it's up again in today's premarket. APDN is trading actively with a 115.4% gain ahead of today's opening bell. Our Take: These are some big numbers, but you're taking on significant downside risk if you jump in this trade now. APDN is up more than 600% since yesterday, and that move could quickly reverse once short-term traders start taking profits off the table. Rigel Pharmaceuticals [RIGL] - Last Close: $1.30 A new licensing deal is giving Rigel Pharma a premarket boost. The biotech firm announced a new licensing deal with Forma Therapeutics for Olutasidenib, a novel mutant IDH1 inhibitor to treat of relapsed or refractory Acute Myeloid Leukemia. According to the Tuesday evening announcement, recent Phase 2 data demonstrates the drug's potential, and the US FDA has accepted Forma's NDA for olutasidenib with a target action date in Feb. 2023. Under the terms of the deal, Forma will receive an upfront payment of $2.0 million, and it's eligible to receive up to $17.5 million in milestone payments with another $215.5 million in commercial milestones on the table. If approved, olutasidenib would be Rigel's second commercial product in hematology-oncology and highly synergistic with Rigel's existing commercial and medical affairs infrastructure RIGL is up 16.9% on active volume following the announcement. Our Take: The market likes this move, and it seems like investors expect olutasidenib to get approved. If the FDA approves it, it's very likely we'll see another large rally in shares of RIGL. However, it will be months before a full approval comes through, so play this one patiently. Invite Your Friends to Join Elite Trade Club and [Start Earning Valuable Rewards Now!](elitetrade.club/referral/?email={EMAIL}) [Image](elitetrade.club/referral/?email={EMAIL}) That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 or [click here]( to sign up now and get our watchlists sent directly to your phone! *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](